leadf
logo-loader
viewAstraZeneca

AstraZeneca completes sale of hypertension drugs rights

The initial US$350mln payment may be followed by optional instalments of up to US$40mln based on sales

AstraZeneca -

AstraZeneca PLC (LON:AZN) rose on Monday as it completed the sale of rights to five medicines used to treat hypertension to private UK company Atnahs Pharma for US$350mln.

The initial payment may be followed by optional instalments of up to US$40mln based on sales, the FTSE 100-listed pharma giant said.

READ: AstraZeneca sells rights for constipation drug to RedHill Biopharma

In 2018, the five drugs - Inderal, Tenormin, Tenoretic, Zestril, Zestoretic - made combined annual sales of US$132mln.

Shares advanced 4% to 7,048p on Monday morning.

Quick facts: AstraZeneca

Price: 6980 GBX

LSE:AZN
Market: LSE
Market Cap: £91.63 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Red Rock Resources advancing towards a Canadian IPO with its Power Metal...

Red Rock Resources PLC (LON:RRR) Chairman Andrew Bell tells Proactive the group has begun the Canadian listing process for its joint venture with Power Metal Resources (LON:POW), Red Rock Australasia Pty Ltd.   Bell says the group is looking to list on the Toronto Stock Exchange...

9 hours, 2 minutes ago

2 min read